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ttp://dx.doi.org/10.1016/j.ajpath.2014.10.003T cells are required to maintain the latency of chronic infection with Toxoplasma gondii in the brain. Here,
we examined the role of noneglutamic acid-leucine-arginine CXC chemokine CXCL9 for T-cell recruitment
to prevent reactivation of infection with T. gondii. Severe combined immunodeﬁcient (SCID) mice were
infected and treated with sulfadiazine to establish a chronic infection. Immune T cells from infected wild-
type mice were transferred into the SCID mice in combination with treatment with anti-CXCL9 or control
sera. Three days later, sulfadiazine was discontinued to initiate reactivation of infection. Numbers of
CD4þ and CD8þ T cells isolated from the brains were markedly less in mice treated with anti-CXCL9 serum
than in mice treated with control serum at 3 days after sulfadiazine discontinuation. Amounts of
tachyzoite (acute stage form of T. gondii)-speciﬁc SAG1 mRNA and numbers of foci associated with
tachyzoites were signiﬁcantly greater in the former than the latter at 5 days after sulfadiazine discon-
tinuation. An accumulation of CD3þ T cells into the areas of tachyzoite growth was signiﬁcantly less
frequent in the SCID mice treated with anti-CXCL9 serum than in mice treated with control serum. These
results indicate that CXCL9 is crucial for recruiting immune T cells into the brain and inducing an accu-
mulation of the T cells into the areas where tachyzoites proliferate to prevent reactivation of chronic
T. gondii infection. (Am J Pathol 2015, 185: 314e324; http://dx.doi.org/10.1016/j.ajpath.2014.10.003)Supported in part by NIH grants AI078756, AI 095032, and AI077877.
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and Molecular Toxicology, Oregon State University, Corvallis, OR.Toxoplasma gondii is an obligate intracellular parasite in
humans and animals. Interferon (IFN)-gemediated immune
responses1,2 and, to a lesser degree, humoral immunity3e5
control the tachyzoite growth during the acute stage of
infection, but the parasite establishes a chronic infection by
forming cysts preferentially in the brain. Chronic infection
with T. gondii is ubiquitous in humans, and 500 million to 2
billion people worldwide are estimated to be chronically
infected with this parasite.6,7 This chronic infection can be
reactivated and develop life-threatening toxoplasmic enceph-
alitis (TE) in immunocompromised persons such as those with
AIDS, neoplastic diseases, and organ transplants.8,9 This factstigative Pathology.
.clearly indicates an importance of the protective immunity to
maintain the latency of chronic infection with T. gondii in the
brain. However, the mechanisms by which the immune
responses prevent reactivation of the chronic infection are not
well understood.
CXCL9 in Resistance to ToxoplasmosisAlthough T. gondii has three major genotypes (types I, II,
and III), type II is predominant in the strains isolated from
patients with TE in North America and Europe.10e12
Therefore, for investigating the mechanisms by which the
immune system maintains the latency of chronic T. gondii
infection and prevents TE, animals that establish a latent,
chronic infection with type II parasite in their brains provide
an excellent model. BALB/c mice are one of those ani-
mals.13,14 IFN-g is essential to maintain the latency of
chronic cerebral infection with T. gondii.15,16 This cytokine
can activate microglia17,18 and astrocytes19e21 to prevent
tachyzoite proliferation. In addition, IFN-g plays an impor-
tant role in regulating recruitment of immune T cells into the
brain of BALB/c mice during both the acute and chronic
stages of infection.22,23 Induction of vascular cell adhesion
molecule 1 (VCAM-1) expression on the cerebral vessels
during the chronic infection is largely mediated by IFN-g,22
and the binding of a4b1 integrin expressed on the surface of
T cells to VCAM-1 expressed on the cerebrovascular endo-
thelial cells is important for inducing prompt recruitment of
immune T cells into their brains during the early stage of
reactivation of chronic T. gondii infection to prevent TE.24
Chemokines, in addition to adhesion molecules, are crucial
for T-cell entry into various organs.25,26 In BALB/c mice
chronically infected with T. gondii, CXCL9, CXCL10, and
CCL5 are the chemokines predominantly expressed in their
brains.27,28 In the present study, we examined the role of
IFN-g in cerebral expression of these three chemokines
during reactivation of the chronic infection in BALB/c-
background immunodeﬁcient mice, and found that the
CXCL9 expression requires IFN-g. On the basis of this
observation, we examined the role of CXCL9 in recruiting
immune T cells into the brain for maintaining the latency of
chronic infection with T. gondii with the use of a model of
reactivation of the infection in severe combined immunode-
ﬁcient (SCID) mice with adoptive transfer of immune T cells
from infected wild-type animals. By applying anti-CXCL9
antiserum in this animal model, the present study revealed
that CXCL9 is crucial for recruiting immune T cells into the
brain and for inducing an accumulation of the T cells around
the areas associated with tachyzoites to prevent reactivation
of cerebral infection with T. gondii.
Materials and Methods
Mice
BALB/c, BALB/c-background SCID, and IFN-gedeﬁcient
(IFN-g/) mice were obtained from The Jackson Labora-
tory (Bar Harbor, ME). Swiss-Webster mice were from
Taconic (Germantown, NY). Mouse care and experimental
procedures were performed under pathogen-free conditions
in accordance with established institutional guidance and
approved protocols from the Institutional Animal Care and
Use Committee. Female mice were used for all studies.
Three to four mice were used in each experimental group.The American Journal of Pathology - ajp.amjpathol.orgInfection with T. gondii
Cysts of the ME49 strain were obtained from brains of
chronically infected Swiss-Webster mice.29,30 All mice were
infected with 10 cysts perorally by gavage. IFN-g/ and
SCID mice were treated with 400 mg/L sulfadiazine in the
drinking water, beginning at 4 to 9 days after infection for 2
to 4 weeks to control the proliferation of tachyzoites and to
establish a chronic infection in their brains.29,31
Puriﬁcation and Transfer of Immune T Cells
Spleen cells were obtained from chronically infected
BALB/c mice and suspended in Hanks’ balanced salt so-
lution (Irvine Scientiﬁc, Santa Ana, CA) with 2% fetal
bovine serum (Sigma-Aldrich, St. Louis, MO). Immune T
cells were puriﬁed from the spleen cells with the use of
magnetic bead-conjugated anti-mouse CD4 (GK1.5) and
anti-mouse CD8 (53-6.7) monoclonal antibodies (mAbs;
Miltenyi Biotech, Auburn, CA) as described previously.29,31
The purity of the T-cell population in each of the prepara-
tions was >94%. A total of 1  107 immune T cells were
injected intravenously into sulfadiazine-treated SCID mice
at 3 to 5 weeks after infection.29,32
Antibody Preparation and Treatment of Mice
Rabbit antisera to CXCL9 were produced by Biosynthesis
(Lewisville, TX) by using synthetic peptide (CISTSRGTI-
HYKSLK, coupled to carrier protein keyhole limpet
hemocyanin) selected from CXCL9 protein.33e35 The antisera
reacted speciﬁcally with the chemokine and blocked T-cell
migration in vivo in previous studies.33e35 SCID mice were
injected intraperitoneally with 0.5 mL of anti-CXCL9 or
control rabbit serum (Life Technologies, Grand Island, NY)
every other day, beginning 1 day before a transfer of the
immune T cells.34,35
Flow Cytometry to Detect T Cells that Migrated into the
Brains of Infected SCID Mice after T-Cell Transfer
Sulfadiazine treatment on infected SCID mice was dis-
continued at 3 days after a systemic transfer of immune
T cells to initiate reactivation of cerebral infection with
T. gondii. Three days later, mononuclear cells were puriﬁed
from brains from each group of mice and pretreated with
anti-FcgII/III receptor mAb (clone 2.4G2) and then incu-
bated with a phycoerythrin-conjugated mAb to CD4 (clone
RM4-5) and ﬂuorescein isothiocyanate- or peridinin-
chlorophyll-protein complex (PerCP)-conjugated mAb to
CD8b (clone 53-6.7) as described previously.36,37 Isotype
control antibodies were used as negative controls. To
examine the numbers of T cells capable of producing IFN-g
in the mononuclear cell preparations from the brains of the
SCID mice that received the T cells, the cells puriﬁed from
the brains were stimulated with phorbol myristate acetate315
Ochiai et aland ionomycin (Sigma-Aldrich) in the presence of Golgi-
Plug (BD Biosciences, Mountain View, CA) as described
previously.31 After the stimulation, the cells were incubated
with PerCP-conjugated anti-CD3 mAbε (clone 145-2C11),
followed by ﬁxation and permeabilization with Cytoﬁx/
Cytoperm Plus kit (BD Biosciences) and stained with
phycoerythrin-conjugated antieIFN-g (XMG1.2) or iso-
type control (R3-34) mAbs.31 All mAbs were purchased
from BD Biosciences. Cells were analyzed on a FACSCa-
libur by using CellQuest Pro software version 6.0 (BD
Biosciences). The staining was triplicated in each group
with the use of pooled cells from mice in the same group or
performed individually on each animal in each experimental
group.
Flow Cytometry to Detect Expression of CXCR3 (CD183)
on CD4þ and CD8þ Immune T Cells of the Spleens and
the Brains of BALB/c Mice Chronically Infected with
T. gondii
Spleen cells and mononuclear cells from the brain were
obtained from chronically infected BALB/c mice and
stained with PerCP-conjugated mAb to CD3, ﬂuorescein
isothiocyanate-conjugated mAb to CD4, phycoerythrin-
conjugated mAb to CD8b, and allophycocyanin-conjugated
anti-CD183 mAb (clone CXCR3-173) as described previ-
ously.36,37 Isotype control antibodies were used as negative
controls. All antibodies were fromBDBiosciences. Cells were
analyzed on a FACSCalibur as described in the previous
paragraph for analyses on the cells puriﬁed from the brains.
Immunohistochemical Analysis for Detection of
T. gondii and CD3þ T Cells in the Brains during
Reactivation of Cerebral T. gondii Infection
The brains of infected SCID mice that had received immune
T cells in combination with treatment with anti-CXCL9 or
control serum were obtained at 5 days after discontinuation
of sulfadiazine treatment and ﬁxed with 10% formalin, 70%
ethanol, and 5% acetic acid. Sagittal sections of the brains
were deparafﬁnized, subjected to antigen retrieval in a
microwave oven, and incubated with 3% hydrogen peroxide
solution for 15 minutes to remove endogenous peroxidase
activity. The slides were then incubated with polyclonal rat
anti-T. gondii serum (from a Sprague-Dawley rat 2 months
after infection with 104 oocysts of the CT 1 strain38) and
with polyclonal rabbit anti-CD3 antibodies (Abcam, Cam-
bridge, MA) at room temperature for 2 hours. After three
washes in Tris-buffered saline (pH 7.6), the slides were
incubated with rabbit-on-rodent alkaline phosphatase-
polymer (Biocare Medical, Concord, CA) and then with
Vulcan Fast Red chromogen (Biocare Medical). After three
washes, the slides were applied to incubation with
peroxidase-conjugated donkey anti-rat IgG antibodies
(Jackson ImmunoResearch Laboratories, West Grove, PA),316followed by incubation with diaminobenzidine peroxidase
substrate kit (Vector Laboratories, Burlingame, CA). Three
or four sections, at least 50 mm apart, were stained in each
brain. Numbers of foci that contained tachyzoites with or
without association with CD3þ T cells in each section were
counted microscopically. The foci associated with at least
three CD3þ T cells were counted as those associated with
T cells. Two persons counted the numbers of foci indepen-
dently, and the mean values from their counts were used for
each animal for comparison between experimental groups.
Quantiﬁcation of mRNA for CXCL9, CXCL10, CCL5,
Tachyzoite-Speciﬁc SAG1, and Bradyzoite-Speciﬁc
BAG1
RNA was isolated from a half brain of each of the infected
SCID and IFN-g/ mice at the last day of sulfadiazine
treatment and 3 and 5 days after discontinuation of the
treatment. The total RNA were pretreated with DNase I
(Invitrogen, Carlsbad, CA) to remove genomic DNA
contaminating the RNA preparations and then applied for
cDNA synthesis.39,40 Real-time PCR for b-actin and CXCL9,
CXCL10, and CCL5 were performed with the cDNA with
StepOnePlus real-time PCR system (Applied Biosystems,
Branchburg, NJ).27 In one experiment, IFN-g/ mice were
injected intravenously with 1 mg (0.2 to 1.0  105 units) of
murine recombinant IFN-g (BD Bioscience) in 0.2 mL of
saline every other day, beginning at 20 days after infection for
three times. As a control, IFN-g/ mice were injected in the
same manner with 0.2 mL of saline. One day after the ﬁnal
injection, RNA was isolated from their brains, and amounts of
mRNA for the chemokines were measured in the same
manner. RNA was also isolated from the brains of infected
SCID mice that had received immune T cells in combination
with anti-CXCL9 or control serum, at 5 days after discontin-
uation of sulfadiazine, and quantiﬁcation of mRNA for
tachyzoite-speciﬁc SAG1 and bradyzoite-speciﬁc BAG1 was
performed as previously described.24,39,40
Statistical Analysis
Levels of signiﬁcance between experimental groups were
determined by Student’s t-test or a nonparametric test by
using GraphPad Prism version 5.0 software (GraphPad Inc.,
La Jolla, CA). P < 0.05 was considered signiﬁcant.
Results
IFN-g Production by Innate Immune Cells Induces
Up-Regulation of CXCL9 Expression in the Brain during
Reactivation of Cerebral Infection with T. gondii
Our previous studies found that a systemic transfer of im-
mune T cells from infected BALB/c mice into infected,
sulfadiazine-treated nude, or SCID mice prevents TE after
discontinuation of sulfadiazine that initiates reactivation ofajp.amjpathol.org - The American Journal of Pathology
Figure 1 Increases in cerebral expression of mRNA for CXCL9, but not for CXCL10 and CCL5, require IFN-g during reactivation of infection with Toxoplasma
gondii. SCID and IFN-g/ mice were infected with 10 cysts of the ME49 strain perorally and treated with sulfadiazine for 3 weeks, beginning 4 to 7 days after
infection. Mice were sacriﬁced on the last day of sulfadiazine treatment and at 3 and 5 days after discontinuation of the treatment that initiates reactivation
of the infection in their brains, and the brains were analyzed for expression of mRNA for the chemokines (see Materials and Methods). Brains of uninfected mice
of each strain were used as controls. Data are expressed as means  SEM. n Z 3 or 4 mice in each experimental group. *P < 0.05, **P < 0.01. IFN-g,
interferon-g; SCID, severe combined immunodeﬁcient; TNF-a, tumor necrosis factor-a.
CXCL9 in Resistance to ToxoplasmosisT. gondii infection.29,32 In contrast, the transfer of T cells
did not prevent TE in infected IFN-g/ mice,29 indicating
IFN-g production by innate immune cells, in addition to
T cells, is required for preventing reactivation of cerebral
T. gondii infection. Because IFN-g is important for inducing
migration of immune T cells into the brains of chronically
infected BALB/c mice,22 it is possible that IFN-g production
by innate immune cells, including microglia, blood-derived
macrophages,41,42 plays an important role in inducing
expression of the chemokine(s) that mediates recruitment of
the T cells into the brains of the infected mice. Because
CXCL9, CXCL10, and CCL5 are the chemokines predom-
inantly expressed in the brains of chronically infected
BALB/c mice,27,28 we examined whether cerebral expres-
sion of any of these three chemokines are induced by IFN-g
produced by innate immune cells during reactivation of
cerebral T. gondii infection.
SCID and IFN-g/ mice were infected and treated with
sulfadiazine to establish a chronic infection in their
brains.29,32 Expression of mRNA for CXCL9, CXCL10, and
CCL5 and for IFN-g and tumor necrosis factor (TNF)-a in
their brains were examined on the last day of sulfadiazine
treatment (day 0) and on day 3 and day 5 afterThe American Journal of Pathology - ajp.amjpathol.orgdiscontinuation of the treatment. Increased amounts of cere-
bral mRNA for each of the three chemokines were detected
on day 0 in both SCID and IFN-g/ mice compared with
uninfected mice of each strain (P < 0.05) (Figure 1). No
differences were found in the amounts of mRNA for these
chemokines between infected SCID and IFN-g/ mice at
this time point. After initiation of reactivation of the cerebral
infection by discontinuation of sulfadiazine, changes in
mRNA amounts in the brains of these mice markedly differed
among these three chemokines. Amounts of CXCL9 mRNA
in the brains of SCID mice on day 5 were 30 times greater
than amounts on day 0 (P < 0.05), whereas amounts of these
mRNA did not differ between days 0 and 5 in the brains of
IFN-g/ mice. In a similar manner, amounts of cerebral
IFN-g mRNA in SCID mice were 123 times greater on day 5
than amounts on day 0 (P < 0.05), whereas IFN-g mRNA
were undetectable in the brains of IFN-g/ mice at both of
these time points as expected (Figure 1). These results indi-
cate that cerebral expression of CXCL9 mRNA markedly
increases during reactivation of T. gondii infection in SCID
mice, and that IFN-g is required for its up-regulation. This
observation is consistent with other models that found a
requirement of IFN-g for CXCL9 expression.43317
Ochiai et alAmounts of CXCL10 mRNA increased in the brains of
both SCID and IFN-g/ mice after discontinuation of
sulfadiazine (Figure 1). However, the amounts of these
mRNA were signiﬁcantly greater in the former than the
latter on each of days 3 and 5 (P < 0.05), suggesting that
the increases in cerebral CXCL10 mRNA after initiation
of reactivation of T. gondii infection partially depends
on IFN-g.
In contrast to the cerebral expression of CXCL9 and
CXCL10, amounts of CCL5 mRNA increased in a similar
manner in both SCID and IFN-g/ mice, and no differ-
ences were found in the amounts of CCL5 mRNA between
these two strains of mice on each of day 3 and day 5
(Figure 1). Therefore, CCL5 mRNA amounts increase in the
brains of these mice independently from IFN-g during
reactivation of cerebral T. gondii infection.
TNF-a mRNA amounts were 6.3 times greater in the
brains of IFN-g/ mice on day 5 than on day 0 (P < 0.05)
(Figure 1). It has been shown that TNF-a can induce
expression of CXCL10 and CCL5 in astrocytes in vitro.44,45
Therefore, the up-regulated expression of TNF-a in the
brains of IFN-g/ mice during reactivation of T. gondii
infection appears to have contributed, at least in part, to in-
creases in cerebral mRNA amounts for CXCL10 and CCL5
in these mice.
In a separate experiment, infected, sulfadiazine-treated
IFN-g/ mice were treated with recombinant IFN-g or saline
every other day for three times, and the cerebral expression of
CXCL9, CXCL10, and CCL5mRNAweremeasured at 1 day
after the ﬁnal treatment. CXCL9 mRNA amounts were ﬁve
times greater in the mice treated with recombinant IFN-g than
in mice treated with saline (ratios to b-actin mRNA amounts,
0.0257  0.0024 versus 0.0055  0.0021 [102];
P< 0.0001). CXCL10 mRNA amounts tended to be slightly
greater in the former than the latter (ratios to b-actin mRNA
amounts, 1.00 0.109 versus 0.78 0.42 [102]), but the
difference did not reach signiﬁcance. No increase was found
in CCL5 mRNA amounts with treatment with recombinant
IFN-g (ratios to b-actin mRNA amounts, 1.31  0.197
versus 1.45 0.657 [102]). These results further support
the IFN-gedependent expression of CXCL9 in the brains
during cerebral infection with T. gondii.
CXCL9 Is Important for Recruiting CD4þ and CD8þ
Immune T Cells into the Brain during the Early Stage of
Reactivation of Cerebral Infection with T. gondii
Because an up-regulation of cerebral CXCL9 expression
during reactivation of T. gondii infection was found to
require IFN-g, it is possible that IFN-gemediated expression
of CXCL9 plays a crucial role in recruiting immune T cells
into the brain during the reactivation of the infection. To
address this possibility, we used adoptive transfer of immune
T cells into infected, sulfadiazine-treated SCID mice in
combination with treatment with anti-CXCL9 serum to
neutralize its activity. Systemic transfer of immune T cells into318these mice before discontinuation of sulfadiazine prevents
reactivation of the infection.29,31 Infected, sulfadiazine-treated
SCID mice received 1  107 immune T cells, and mice were
treated with anti-CXCL9 serum every other day, beginning at
1 day before the cell transfer. As a control, another group of
infected SCID mice that had received T cells were treated
with normal serum in the same manner. Sulfadiazine
treatment was discontinued at 3 days after the T-cell
transfer. At 3 days after discontinuation of sulfadiazine,
numbers of CD4þ and CD8þ T cells that had migrated into
the brains of SCID mice were examined by ﬂow cytometry.
Percentages of CD4þ and CD8þ T cells in mononuclear
cells puriﬁed from the brain were signiﬁcantly lower in the
SCID mice treated with anti-CXCL9 serum than in mice
treated with control serum (P < 0.01) (Figure 2A). In
addition, numbers of CD4þ and CD8þ T cells in the cell
preparations were ﬁve and three times less in the former
than the latter, respectively (P < 0.001 and P < 0.01,
respectively) (Figure 2B). These results indicate that
CXCL9 plays a crucial role in recruiting both CD4þ and
CD8þ T cells into the brains during the early stage of
reactivation of cerebral infection with T. gondii.
CXCL9 Is Important for Recruitment of IFN-gþ T Cells
into the Brains during the Early Stage of Reactivation
of Cerebral Infection with T. gondii
IFN-g can activate microglia17,18 and astrocytes19e21 to
prevent tachyzoite proliferation. Because IFN-g production
by T cells is required for maintaining the latency of chronic
infection with T. gondii in BALB/c mice,32 we performed a
ﬂow cytometric analysis to measure numbers of T cells
capable of producing IFN-g in the brains of SCID mice that
had received immune T cells with treatment with anti-
CXCL9 or control serum, at 3 days after discontinuation
of sulfadiazine treatment. Numbers of IFN-gþCD3þ T cells
in the brains of the mice treated with anti-CXCL9 serum
were one-half of those in the brains of mice treated with
control serum (P < 0.001) (Figure 2C). Therefore, CXCL9
is important for recruiting immune T cells capable of pro-
ducing IFN-g into the brain during the early stage of reac-
tivation of T. gondii infection.
CXCR3 (CD183) Is Expressed on the Surface of Both
CD4þ and CD8þ T-Cell Populations in the Spleens of
BALB/c Mice Chronically Infected with T. gondii
CXCL9 directs the trafﬁcking of activated effector T cells by
binding to its high-afﬁnity receptor CXCR3 expressed on the
surface of the T cells.43,46,47 To further conﬁrm the importance
of CXCL9 for recruiting immune T cells into the brain during
reactivation of cerebral T. gondii infection, we examined an
expression of CXCR3 on the surface of splenic CD4þ and
CD8þ immune T cells of chronically infected BALB/c mice,
which were transferred into infected SCID mice. On average,
36.7% of CD4þ and 47.7% of CD8þ T cells in the spleens ofajp.amjpathol.org - The American Journal of Pathology
CXCL9 in Resistance to Toxoplasmosisinfected BALB/c mice were positive for CXCR3 on their
surface (Figure 3, A and B). These ratios of CXCR3þ
population in the T cells were signiﬁcantly higher than those
of the T cells in the spleens of uninfected mice (19.5% for
CD4þ T cells and 30.0% for CD8þ T cells; P < 0.05 and
P < 0.01, respectively) (Figure 3, A and B), indicating that
T. gondii infection up-regulates CXCR3 expression on both
CD4þ and CD8þ T cells in the spleen. We also examined
CXCR3 expression on the T cells that had inﬁltrated into
their brains. In contrast to the splenic T cells, each of CD4þ
and CD8þ T cells puriﬁed from their brains did not have two
distinct populations, CXCR3þ and CXCR3, and had a
single population whose median ﬂuorescence intensity for
CXCR3 was close to the ﬂuorescence intensity of the cutoff
value to distinguish CXCR3þ and CXCR3 populations of
the splenic T cells (Figure 3C). It has been shown that
CXCL9 and the two other CXCR3 ligands, CXCL10 and
CXCL11, induce down-regulation of CXCR3 expression on
T cells.48,49 Therefore, it is likely that most of both CD4þ
and CD8þ T cells that migrated into the brains of infected
mice were originally CXCR3þ, and that their expression of
this molecule has been down-regulated after their inﬁltra-
tion mediated by CXCR3 into the brain.Figure 2 Neutralization of CXCL9 inhibits recruitment of CD4þ and CD8þ
T cells and IFN-gþ T cells into the brain during the early stage of reactivation
of cerebral infection with Toxoplasma gondii. SCID mice were infected with
10 cysts of the ME49 strain perorally and treated with sulfadiazine, begin-
ning at 9 days after infection. A total of 1  107 total T cells were injected
intravenously into the SCID mice at 3 to 5 weeks after infection. Mice were
also injected intraperitoneally with 0.5 mL of anti-CXCL9 serum or control
rabbit serum every other day, beginning at 1 day before the transfer of the T
cells. Three days after the T-cell transfer, sulfadiazine treatment was dis-
continued to initiate reactivation of cerebral T. gondii infection. Mono-
nuclear cells were puriﬁed from their brains at 3 days after discontinuation of
sulfadiazine, and the frequencies (A) and numbers (B) of CD4þ and CD8þ T
cells in the cell preparations were determined by ﬂow cytometry (see
Materials and Methods). A: The results of one of two independent experi-
ments performed. B: The average of the two independent experiments. P
values are shown for each of the two experiments. In a separate experiment,
the mononuclear cells puriﬁed from the brains were stimulated with phorbol
myristate acetate and ionomycin and stained for CD3 and IFN-g, followed by
ﬂow cytometric analysis (see Materials and Methods). C: The numbers of IFN-
gþ T cells in the cell preparations. Data are expressed as means  SDs from
triplicated staining in each experimental group. **P < 0.01, ***P < 0.001.
IFN-g, interferon-g; SCID, severe combined immunodeﬁcient.CXCL9 Is Important for Inducing an Accumulation of T
Cells around the Areas Associated with Tachyzoites and
Preventing Tachyzoite Proliferation in the Brain during
Reactivation of Cerebral Infection with T. gondii
Because neutralization of CXCL9 by anti-CXCL9 serum
inhibited recruitment of immune T cells into the brain during
reactivation of infection with T. gondii, we examined whether
the treatment with anti-CXCL9 serum assists in proliferation
of tachyzoites during the reactivation of infection. We
examined the amounts of mRNA for tachyzoite-speciﬁc
SAG1 in the brains of infected SCID mice at 5 days after
discontinuation of sulfadiazine treatment. Amounts of SAG1
mRNA detected in the brains of SCID mice that had received
immune T cells with treatment with anti-CXCL9 serum were
9.3 times greater than those detected in the brains of mice that
had received the T cells with control serum (P < 0.001)
(Figure 4A). The amounts of SAG1mRNA in the former were
9.5 times less than those detected in the brains of mice that did
not receive T cells (P < 0.01) (Figure 4A). These results
strongly suggest that T-cell recruitment mediated by CXCL9
is critical for preventing tachyzoite growth during reactivation
of chronic infection with T. gondii in the brain, although T-cell
migration not mediated by CXCL9 is also able to partially
inhibit the tachyzoite proliferation.
We also examined the amounts of mRNA for bradyzoite-
speciﬁc BAG1 in the brains of infected SCID mice that had
received immune T cells with treatment with anti-CXCL9 or
control serum at 5 days after discontinuation of sulfadiazine
treatment. Amounts of BAG1 mRNA detected in the brains of
themice treated with anti-CXCL9 serumwere 41% greater thanThe American Journal of Pathology - ajp.amjpathol.orgthose detected in the brains of mice treated with control serum
(P < 0.05). Because the former had 9.3 times greater amounts
of tachyzoite-speciﬁc SAG1 mRNA than the latter, it appears
that a small portion of tachyzoites proliferating in the brains of
the former converted to bradyzoites to form new tissue cysts.319
Figure 3 CXCR3 (CD183) is expressed on both CD4þ and CD8þ immune
T cells in the spleens of BALB/c mice chronically infected with Toxoplasma
gondii. Spleen cells were obtained from uninfected and chronically infected
BALB/c mice and stained for CD3, CD4, CD8, and CXCR3, followed by ﬂow
cytometric analysis. T cells that inﬁltrated into the brains of infectedmice were
analyzed in the same manner. A: The spleen cells were gated on CD3þCD4þ or
CD3þCD8þ T cells, and each of these gated cell populations was analyzed for
their CXCR3 expression. B: Numbers of CXCR3þ population in each of the CD4þ
and CD8þ T cells in the spleen of uninfected and infected mice. C: Comparison
of expression of CXCR3 in CD3þCD4þ and CD3þCD8þ T cells between the spleen
and the brain of infected animal. Data are representative plots from three
independent experiments (A) or expressed as means  SEM from three inde-
pendent experiments (B); representative histograms from two individual mice
(C). *P < 0.05, **P < 0.01.
Ochiai et alTo further evaluate an importance of CXCL9-mediated
T-cell recruitment to prevent reactivation of cerebral T.
gondii infection, we performed immunohistochemistry for
detecting T. gondii in combination with staining for CD3.
Numbers of foci associated with tachyzoites were 4.2 times
greater in the brains of SCID mice that had received immune
T cells in combination with anti-CXCL9 serum treatment
than in the brains of mice that had received the T cells with
control serum (P < 0.05) (Figure 4B). In addition, only the
latter had signiﬁcantly fewer foci associated with tachyzoites
than did control mice that had received no T cells (P < 0.05)
(Figure 4B).
Of importance, most of the foci associated with tachy-
zoites in the SCID mice that had received immune T cells
with treatment with control serum contained only small
numbers of tachyzoites (Figure 4D) or fragments of the
parasite and antigens most likely released from the
destroyed parasites (Figure 4E). Those foci were often
associated with inﬂammatory cells, including CD3þ T cells
that inﬁltrated into the areas (Figure 4, CeE). These results
suggest that in the mice treated with control serum, im-
mune T cells promptly inﬁltrate into the areas of tachyzoite
growth when the parasite numbers are still low, and that320the T cells efﬁciently inhibit the parasite growth and
eventually kill them. In contrast, many of the foci in the
brains of mice treated with anti-CXCL9 serum contained
large numbers of tachyzoites but only small numbers of
inﬂammatory cells, including CD3þ T cells (Figure 4F).
The frequencies of association of T cells in these foci in the
anti-CXCL9 serum-treated mice were only one-third of
those observed in the control serum-treated mice
(P < 0.01) (Figure 4C). In addition, the foci with tachy-
zoite proliferation in the anti-CXCL9 serum-treated mice
were often associated with necrosis of brain tissue
(Figure 4F). These results together indicate that CXCL9 is
crucial for inducing an accumulation of immune T cells
into the areas where tachyzoites started proliferating and
for preventing tachyzoite growth and destruction of brain
tissues by the parasite during reactivation of chronic
infection with T. gondii.Discussion
The present study found that cerebral expression of none
glutamic acid-leucine-arginine CXC chemokine CXCL9ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Neutralization of CXCL9 assists in tachyzoite proliferation in the brains of SCID mice that received immune T cells during reactivation of cerebral
infection with Toxoplasma gondii. SCID mice were infected with 10 cysts of the ME49 strain perorally and treated with sulfadiazine, beginning at 9 days after
infection. A total of 1  107 total T cells were injected intravenously into the SCID mice at 3 to 5 weeks after infection. Mice were also injected intraper-
itoneally with 0.5 mL of anti-CXCL9 serum or control rabbit serum every other day, beginning at 1 day before the transfer of the T cells. At 5 days after
discontinuation of sulfadiazine, RNA was puriﬁed from their brains, and the amounts of mRNA for tachyzoite-speciﬁc SAG1 and bradyzoite-speciﬁc BAG1 was
determined by real-time RT-PCR (see Materials and Methods) (A). BeF: Immunohistochemical studies that stained for T. gondii (brown) in combination with
CD3 (red) were also performed (see Materials and Methods), and numbers of foci that contained tachyzoites with and without an accumulation of CD3þ T cells
were counted microscopically. B: Total numbers of foci associated with tachyzoites per sagittal section. C: Percentages of tachyzoite-containing foci asso-
ciated with CD3þ T cells. DeF: Arrows indicate representatives of parasitophorous vacuoles that contained tachyzoites. Arrowheads indicate representatives
of CD3þ T cells. A representative image of foci that contained a small number of tachyzoites associated with accumulated CD3þ T cells (D), and a repre-
sentative image of the foci that contained destroyed tachyzoites and antigens most likely released from the destroyed parasite (E) in the brains of mice treated
with control serum. F: A representative image of the foci containing a large number of tachyzoites associated with necrosis of brain tissue in the mice treated
with anti-CXCL9 serum. Data are expressed as means  SEM (AeC). nZ 4 mice in each experimental group. *P < 0.05, **P < 0.01, and ***P < 0.001. SCID,
severe combined immunodeﬁcient.
CXCL9 in Resistance to Toxoplasmosisincreases in an IFN-gedependent manner during reactivation
of T. gondii infection, and that this chemokine is crucial for
recruiting immune T cells into the brain and for preventing
the parasite growth and reactivation of the infection. These
observations were obtained in a model of reactivation of
T. gondii infection in chronically infected BALB/
c-background SCID mice that received a systemic transfer
of immune T cells. Because our previous study found that
CXCL9 is one of the three major chemokines expressed in
the brains of chronically infected wild-type BALB/c
mice,27 and because the protein amount of the CXCL9 is
the highest among these three chemokines in their brains,27
it is most likely that CXCL9 plays an important role in
recruiting immune T cells into the brains of infected BALB/
c mice to prevent reactivation to the infection. An impor-
tance of CXCL9 for host resistance in the brain was pre-
viously reported in viral infections.34,50,51 In infection with
mouse hepatitis virus, CXCL9 is important for mediating
T-cell recruitment and host defense against the virus in the
brain.34,50 CXCL9 is also critical in controlling herpes
simplex virus-2 in the spinal cord and brainstem byThe American Journal of Pathology - ajp.amjpathol.orgrecruiting natural killer cells and/or CD8þ T cells to the
sites of infection after genital infection with the virus.51
The present study found an importance of CXCL9 for
T-cell recruitment to the areas where tachyzoites begin
proliferating to prevent reactivation of cerebral infection
with T. gondii, an intracellular protozoan parasite. There-
fore, CXCL9 plays a crucial role in host defense against
infection with multiple types of intracellular microorgan-
isms in the brain.
In contrast to the observations in the present study on the
importance of CXCL9 for host resistance against reactivation
of chronic cerebral infection with T. gondii, it was reported
that there is no signiﬁcant differences in mortality between
CXCL9-deﬁcient and wild-type C57BL/6 mice during an
acute primary infection with the parasite.52 The expression of
CXCL9 increases in the brain only during the later stage of
T. gondii infection,53,54 whereas mortality during the acute
stage is associated with parasite growth in the peripheral
organs. Therefore, it is possible that the role of CXCL9 in
resistance to the parasite differ, depending on the stages of
infection and likely depending on the organs. In relation to321
Ochiai et althis possibility, a recent study found that increased mortality
to acute infection with T. gondii occurs in CXCR3-knockout
mice after oral but not intraperitoneal infection.55
The present study used BALB/c mice that are genetically
resistant to chronic infection with type II T. gondii and are
able to maintain the latency of the infection. In contrast,
C57BL/6 mice are genetically susceptible to the infection
and develop progressive and ultimately fatal TE during the
later stage of the infection.13,14 In the use of susceptible
C57BL/6 mice, it was shown that CXCL10 is important for
recruitment of CD8þ T cells into the brain and inhibiting
tachyzoite proliferation during the progressive TE.56 CCR2
was also shown to be involved in migration of CD4þ T cells
and macrophages into the brains and inhibiting tachyzoite
growth in these mice.57 Both CXCL9 and CXCL10 exert a
potent chemotactic effect on T cells by binding to the shared
receptor CXCR3.43,46,47 Our previous study demonstrated
that CXCL9 protein amounts in the brain of chronically
infected BALB/c mice are signiﬁcantly greater than those of
CXCL10.27 Therefore, one possibility would be that
CXCL9 plays a major role in CXCR3-mediated recruiting
immune T cells into the brains of resistant BALB/c mice,
whereas CXCL10 does the similar role in susceptible
C57BL/6 mice.
Another possibility is that CXCL9 and CXCL10 are
both involved in T-cell recruitment into the brain during
cerebral infection with T. gondii. Despite sharing the
identical receptor, each of CXCL9 and CXCL10 was found
to be important for resistance to infections in the brain with
mouse hepatitis virus34,50 and herpes simplex virus-251 in
an identical murine model of each of these diseases.
Similarly, each of these two chemokines is involved in the
development of cerebral murine malaria, in which CD8þ T
cells play an important pathogenic role.58 In the model of
cerebral malaria, CXCL9 was detected in endothelial cells
in the brain, whereas CXCL10 was detected mostly in
neurons.58 In cerebral T. gondii infection, microglia have
been shown to express CXCL9 mRNA, whereas CXCL10
mRNA is expressed mostly by astrocytes in infected
BALB/c mice.23 Therefore, the expression of CXCL9 and
CXCL10 by different cell populations in different loca-
tions might contribute to the importance of each of these
two chemokines in recruitment of pathogen-speciﬁc T cells
into the brain during cerebral infection with intracellular
microorganisms. This possibility may be supported by the
evidence in the present study that anti-CXCL9etreated
mice were partially able to control tachyzoite growth
during the reactivation of cerebral T. gondii infection.
Our recent study found that IFN-geinduced expression of
endothelial VCAM-1 and its binding to a4b1 integrin on
immune T cells is important for prompt recruitment of the T
cells into the brain and prevention of TE during reactivation of
T. gondii infection.24 The present study revealed the impor-
tance of CXCL9, whose expression requires IFN-g, for the T-
cell recruitment to the brain and for inducing an accumulation
of recruited T cells into the areas of tachyzoite proliferation to322control the parasite during the reactivation of the infection.
Therefore, IFN-g regulates T-cell inﬁltration into the brain by
inducing an expression of both the adhesion molecule and the
chemokine critical for the T-cell migration into the brain to
prevent tachyzoite growth and reactivation of cerebral infec-
tion with T. gondii.References
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